Altre lingue Zydus Lifesciences Limited

Azioni

ZYDUSLIFE

INE010B01027

Tempo differito NSE India S.E. Altri mercati azionari 12:26:41 25/04/2024			Variaz. 5gg	Var. 1 gen.
951,2 ^INR	+1,90%		+1,52%	+38,02%

24/04	Zydus Lifesciences riceve 10 osservazioni dalla FDA statunitense dopo l'ispezione del sito produttivo di Jarod, India	MT
23/04	Zydus Lifesciences Limited annuncia l'accettazione in Cina della domanda di registrazione di un nuovo farmaco innovativo, Desidustat compresse, da parte di China Medical System Holdings Limited.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	24/04
China Medical System's Anti-Anaemia NDA Accepted in China	23/04
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23/04
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	23/04
Zydus launches Mirabegron Extended-Release Tablets in the US	22/04
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	22/04
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	22/04
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	22/04
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	01/04
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	28/03
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	23/03
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	18/03
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	16/03
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	15/03
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	14/03
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	14/03
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	14/03
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	13/03
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib	13/03
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection	11/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Zydus Lifesciences Limited

Azioni

ZYDUSLIFE

INE010B01027

Altre lingue

Filtri